September 17th 2025
Alteogen received a positive CHMP opinion for EYLUXVI in July 2025
September 4th 2025
Dr Ramtohul's research uses electrophysiologic testing to study the retinal ganglion cells
September 3rd 2025
The US Food and Drug Administration (FDA) also granted RMAT designation for MCO-010 in Stargardt disease (SD).
September 1st 2025
Presentation topics will include therapies for age-related macular degeneration, X-linked retinitis pigmentosa and other retinal pathologies
August 28th 2025
Clinical leaders including Susan Schneider, MD; Lejla Vajzovic, MD; and Harvey Uy, MD, will share new clinical findings
How remote retinal imaging raises the bar across service, research and education
Prof Baljean Dhillon advocated for remote practices and provided advice for implementation at the International SPECTRALIS Symposium
Modern monitoring strategies remove major barriers to retina care
Anat Loewenstein, MD, presented real-world results of remote imaging at the International SPECTRALIS Symposium
Differentiating physiology from pathology in the paediatric vitreous
Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture
Tyson Brunstetter, OD, PhD, shares key takeaways from his keynote at the International SPECTRALIS Symposium
Dr Brunstetter, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, delivered the lecture at this year's ISS alongside his colleague Warren Hoburg
Imaging the ellipsoid zone line could change the global approach to clinical trials
Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium
Neeraj Dhaun, MD, PhD, says advances in OCT tech may positively impact patients with chronic kidney disease
Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium
Gereon Hüttmann, PhD, introduces holographic OCT to a new audience
The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium
Ruth Hogg, PhD, says NICOLA data emphasise the value of multicolor images
Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium
Brazil’s ANVISA grants marketing authorisation to Lucentis biosimilar FYB201 (Ranivisio, Formycon/Bioeq AG)
Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.
An implantable option bridges the gap for patients with AMD
Long-term benefits and vision preservation using an extended macular vision IOL
EU issues CE mark for AI therapy planning assistant from deepeye Medical
The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe
Metabolomic profiling could identify stage-specific diabetic retinopathy biomarkers
Lysine, proline and arginine levels progressively increased from non-proliferative DR to proliferative DR stages
Research indicates B vitamins and choline provide neuroprotection against glaucoma
Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death
EMA issues CE mark for DREAM OCT (Intalight)
The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities
ARVO 2025: Ocular and systemic mitochondrial diseases may be key to dementia diagnosis
Detecting mitochondrial dysfunction may give clinicians a chance to reduce the rate of cognitive decline in patients with dementia
AAVantgarde Bio presents positive data for retinitis pigmentosa and Stargardt disease therapies
The company shared results from the AAVB-081 clinical programme and AAVB-039 preclinical programme at ARVO
Retinal microvascular changes in patients with systemic lupus erythematosus: Importance of OCTA
The biomarkers are especially crucial for patients with lupus nephritis
ARVO 2025: Alfredo Sadun, MD, PhD, says "later is better" for some LHON interventions
At the 2025 ARVO annual meeting, Prof Sadun shared an exciting update in our understanding of Leber hereditary optic neuropathy
Moorfields, Topcon, IoO announce partnership launch of Cascader
Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.
ARVO 2025: Nitish Mehta, MD, provides real-world insights from aflibercept 8 mg for treatment-naive diabetic macular oedema
ARVO 2025: Anat Loewenstein, MD, and colleagues on meeting needs of patients with diabetic retinopathy
Prof Loewenstein and a cohort of colleagues assessed the current treatment outlook for patients with diabetic retinopathy
LuxIA receives CE-MDR certification
LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.
Daniela Ferrara appointed by Topcon Healthcare as CMO
Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy
Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch
The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)
Regeneron announces US FDA complete response letter for aflibercept 8 mg (Eylea HD) supplemental Biologics License Application
The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg
DMO study meta-analysis illuminates how racial subgroups are underrepresented in clinical trials
The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab
Artificial intelligence analyses biomarker changes in neovascular AMD treated with faricimab
The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase
Journal of Neuroinflammation publishes data on Eleva’s lead retinal asset CPV-104
In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease
Alcon marks 110th anniversary of Grieshaber AG site in Switzerland
Alcon acquired the historic ophthalmic instrument company in 2000
Eyestem Research announces positive results from phase 1 geographic atrophy trial
Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting